Zobrazeno 1 - 10
of 13
pro vyhledávání: '"Mirela Hategan"'
Autor:
Duncan I. Jodrell, Daniel H. Palmer, Sarah Halford, J. Evans, Lisa V. Hampson, Balaji Venugopal, Robert McLeod, Mirela Hategan, Natalie Cook, Helen Turner, Donna Michelle Smith, Bristi Basu, Aarthi Gopinathan, Michael Nebozhyn, D. Alan Anthoney, David A. Tuveson, William P. Steward, David Propper, Hayley Farmer-Hall
Publikováno v:
Cook, N, Basu, B, Smith, D M, Gopinathan, A, Evans, J, Steward, W P, Palmer, D, Propper, D, Venugopal, B, Hategan, M, Anthoney, D A, Hampson, L V, Nebozhyn, M, Tuveson, D, Farmer-Hall, H, Turner, H, McLeod, R, Halford, S & Jodrell, D 2018, ' A phase i trial of the c-secretase inhibitor MK-0752 in combination with gemcitabine in patients with pancreatic ductal adenocarcinoma ', British Journal of Cancer, vol. 118, no. 6, pp. 793-801 . https://doi.org/10.1038/bjc.2017.495
British Journal of Cancer
British Journal of Cancer
Background: The Notch pathway is frequently activated in cancer. Pathway inhibition by g-secretase inhibitors has been shown to be effective in pre-clinical models of pancreatic cancer, in combination with gemcitabine. Methods: A multi-centre, non-ra
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::45456c3b7d8810792b891ee0674468b1
https://doi.org/10.1038/bjc.2017.495
https://doi.org/10.1038/bjc.2017.495
Autor:
Simon Pacey, Paul M. Loadman, Gareth Griffiths, Alison Young, Margaret A. Knowles, Tracie-Ann Madden, Alison Birtle, Mirela Hategan, John D. Chester, Robert Jones, Sanjeev Kumar, Richard Adams, Angela C. Casbard, Javier Garcia Corbacho, Andrew Protheroe
Background: gemcitabine (G) and cisplatin (C) is a standard-of-care, combination chemotherapy regimen for neoadjuvant treatment of muscle-invasive and palliative treatment of advanced bladder cancer (BC). More effective regimens are urgently needed,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f38fcb7ea53c7acc828f1f3cbdfe7283
https://www.repository.cam.ac.uk/handle/1810/286033
https://www.repository.cam.ac.uk/handle/1810/286033
Autor:
Mirela Hategan, Andrea Machin, Wanfeng Zhao, Nimish Shah, Sanjeev Srinivas Kumar, Wendi Qian, Barry R. Davies, Anne Y. Warren, Javier Garcia Corbacho, Susan Ingle, Simon Pacey, Elizabeth A. Harrington, Richard D. Baird, Ola Bratt, Elisabeth Oelmann, Sara Stearn, Vincent Gnanapragasam
Publikováno v:
Journal of Clinical Oncology. 36:5081-5081
5081Background: The effect of novel drugs can be studied in primary prostate cancer (PC), if given prior to radical prostatectomy (RP). Altered PI3K/AKT/mTOR signalling is associated with aggressiv...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::74367e6730fee53b934c410fd365eb3b
https://doi.org/10.1200/jco.2018.36.15_suppl.5081
https://doi.org/10.1200/jco.2018.36.15_suppl.5081
Autor:
James Spicer, Michael Sheaff, Sukaina Rashid, Amanda Johnston, Melissa Phillips, Ramsay Khadeir, Simon Pacey, Gary Cook, John S. Bomalaski, Peter W. Szlosarek, Teresa Szyszko, Jeremy P.C. Steele, Mirela Hategan, Jonathan Shamash, Peter E Hall, Xiaoxing Feng
Publikováno v:
Journal of Clinical Oncology. 35:8553-8553
8553 Background: Argininosuccinate synthetase 1 (ASS1)-deficient malignant pleural mesothelioma (MPM) cells are sensitive to arginine deprivation with pegylated arginine deiminase (ADI-PEG20), which also potentiates the cytotoxic effect of pemetrexed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::94737f94478a9b6cc444a24e62ef4156
https://doi.org/10.1200/jco.2017.35.15_suppl.8553
https://doi.org/10.1200/jco.2017.35.15_suppl.8553
Autor:
Vincent J. Gnanapragasam, Javier Garcia Corbacho, Elisabeth Oelmann, Sanjeev Kumar, Sara Stearn, Simon Pacey, Richard D. Baird, Ola Bratt, Wanfeng Zhao, Susan Ingle, Nimish Shah, Anne Y. Warren, Mirela Hategan, Elizabeth A. Harrington, Wendi Qian, Barry R. Davies, Leanne K Bell, William Dott
Publikováno v:
Journal of Clinical Oncology. 35:97-97
97 Background: Additional systemic therapy given to unselected patients (pts) around RP has yet to improved pt survival. Further trials should use appropriate pt selection, i.e. men at highest risk of relapse, ideally biomarker stratified. Using nove
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::bc48e9fcdb10d11e8ed26d8a588b4a5e
https://doi.org/10.1200/jco.2017.35.6_suppl.97
https://doi.org/10.1200/jco.2017.35.6_suppl.97
Publikováno v:
British medical bulletin. 111(1)
Background Melanoma is a potentially curable cancer, but around 20% of patients will develop disease which is beyond surgical clearance. Rising incidence alongside breakthroughs in understanding the molecular biology of this disease identifying syste
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::de9da1b4e8e6fa55e0ee04ee34e411e7
https://pubmed.ncbi.nlm.nih.gov/25190764
https://pubmed.ncbi.nlm.nih.gov/25190764
Autor:
James Larkin, Pippa Corrie, Cristian Ciria, Nicholas Coupe, Mark R. Middleton, L Collins, Sharon Love, Avinash Gupta, Adelyn Wise, Mirela Hategan, Sam Suter, Martin Gore
Publikováno v:
European journal of cancer (Oxford, England : 1990). 51(3)
Background We sought to determine the maximal tolerated dose of the MEK inhibitor trametinib with weekly paclitaxel, with a view to exploring the combination’s activity in melanoma lacking a BRAF V600 mutation. Methods In this phase 1 study we used
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::49f234ea820161626825b4211753c3d7
https://pubmed.ncbi.nlm.nih.gov/25542057
https://pubmed.ncbi.nlm.nih.gov/25542057
Autor:
Mirela Hategan, Ioannis Karydis, Philippa Corrie, Matthew Wheater, Christian H. Ottensmeier, Sarah Gabrielle Ellis, Nicola Price, Lalit Pallan, Marianne Nicolson, Hendrik-Tobias Arkenau, Neil Steven
Publikováno v:
Journal of Clinical Oncology. 34:e21027-e21027
e21027Background: Combination BRAF and MEK inhibition in mm has demonstrated improved Overall Survival (OS) and Progression Free Survival (PFS) compared to single agent BRAF inhibition (BRAFi) in p...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7eb5141ff1fdb22192d1612d0ce9983
https://doi.org/10.1200/jco.2016.34.15_suppl.e21027
https://doi.org/10.1200/jco.2016.34.15_suppl.e21027
Autor:
William Dott, Carlos Caldas, James D. Brenton, Sanjeev Kumar, Maricica Zabrautanu, Hedley Carr, Nitzan Rosenfeld, Francesco Marrass, Javier Garcia-Corbacho, Mirela Hategan, Brian Dougherty, James Anthony Morris, Richard D. Baird, Davina Gale, Duncan I. Jodrell, Florent Mouliere, Elizabeth A. Harrington, J. Carl Barrett, Bristi Basu, Simon Pacey
Publikováno v:
Journal of Clinical Oncology. 34:11530-11530
11530Background: Serial analysis of plasma ctDNA with next generation sequencing could be used to identify patients for matched molecular therapies, to monitor the relative abundance of mutations o...
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a00bd2ed2d0361f560ecc6f88dfbed5
https://doi.org/10.1200/jco.2016.34.15_suppl.11530
https://doi.org/10.1200/jco.2016.34.15_suppl.11530
Autor:
Monica Diaz, James Spicer, Michael Sheaff, Amanda Johnston, John S. Bomalaski, Gary J R Cook, Peter Schmid, Teresa Szyszko, Jose Roca, Mirela Hategan, Simon Pacey, Jeremy P.C. Steele, Pui Ying Chan, Ramsay Khadeir, Richard D. Baird, Peter W. Szlosarek, Adelberto Barba, Dimitra Repana
Publikováno v:
Molecular Cancer Therapeutics. 14:B23-B23
Background: Loss of the metabolic tumor suppressor, argininosuccinate synthetase (ASS1), the rate-limiting enzyme in arginine biosynthesis, sensitizes mesothelioma and lung carcinoma cells to apoptosis following arginine withdrawal. We have reported
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2afd3e59e90879f78db4c4f1629b0673
https://doi.org/10.1158/1535-7163.targ-15-b23
https://doi.org/10.1158/1535-7163.targ-15-b23